Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026. In terms of the Company''s Code of Conduct for prevention of Insider Trading, the ''Trading window'' for dealing in the securities of the Company will be closed from Wednesday, 1st July, 2026 till Saturday, 25th July, 2026 (both days inclusive) for the purpose of financial results.

pdf

Cipla Ltd.

22 Jun 2026

1440.10

0.15%

Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?

Economic Times

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla Ltd.

18 Jun 2026

1440.10

0.15%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper advertisement titled ''Notice to shareholders for transfer of shares to the Investor Education and Protection Fund''

pdf

Cipla Ltd.

16 Jun 2026

1440.10

0.15%

Cipla appoints Shivam Puri as CEO of 'One India Business' from July 1

Business Standard

Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.

Cipla Ltd. has an average target of 1553.22 from 9 brokers.

Cipla Ltd.

16 Jun 2026

1440.10

0.15%

Cipla expands respiratory, specialty manufacturing across India, China, US

Business Standard

The drugmaker has approved investments of over Rs 4,000 crore in the past two years to expand respiratory APIs, oncology ingredients, inhalation products and global manufacturing capacity